• Biohaven signed a regional licensing deal with Ono Pharma for its MoDE pan-IgG degrader portfolio in Japan, South Korea, Taiwan, ASEAN.
• Near-term consideration up to USD 100 million, including USD 80 million upfront, USD 20 million milestone expected within one year.
• Biohaven to receive royalties of about 20% on Ono’s net sales in the licensed territory.
• Lead asset BHV-1300 is in Phase 3 for Graves’ disease; agreement also covers follow-on candidates BHV-1310, BHV-1320.
• Biohaven retains rights outside the licensed territory, including the US, Europe, China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610080400PR_NEWS_USPR_____NE65853) on October 08, 2026, and is solely responsible for the information contained therein.